Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 3/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275036 | 0.90 | TARS1 (0.46) | AHCYDOT1LADORA3ADORA1ADORA2A | |
| SCHEMBL30862415 | 0.90 | TARS1 (0.46) | AHCYDOT1LADORA3ADORA1ADORA2A | |
| SCHEMBL2185027 | 0.90 | TARS1 (0.46) | AHCYDOT1LADORA3ADORA1ADORA2A | |
| SCHEMBL29435121 | 0.84 | TARS1 (0.38) | ADORA1 | |
| SCHEMBL28564130 | 0.84 | TARS1 (0.38) | ADORA1 | |
| SCHEMBL16987222 | 0.84 | TARS1 (0.38) | ADORA1 | |
| SCHEMBL29089525 | 0.80 | TARS1 (0.39) | ADORA1 | |
| SCHEMBL2033389 | 0.80 | ADORA1 (0.38) | ADORA3ADORA1ADORA2A | |
| SCHEMBL21274225 | 0.80 | TARS1 (0.37) | ADORA3ADORA1ADORA2A | |
| SCHEMBL30037173 | 0.80 | ADORA1 (0.38) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599679-B2 | Circular RNA compositions | ORNA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250262324-A1 | Circular RNA Compositions | ORNA THERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599679-B2 | Circular RNA compositions | BCL6, BCL9, BCL6B | AHCY 3454/4885DOT1L 2399/4885PRMT1 332/4885 |
| US-20250262324-A1 | Circular RNA Compositions | BCL9, IGF2BP1, BCL6 | AHCY 4602/4885DOT1L 3028/4885PRMT1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.